Abstract
Autoimmune pancreatitis (AIP) is a steroid-responsive fibroinflammatory disorder with two clinically distinct subtypes known as type 1 autoimmune and type 2 autoimmune pancreatitis. Type 1 AIP is considered the pancreatic manifestation of Immunoglobulin G4-related disease (IgG4-RD); a systemic disease often presenting with other organ involvement. Advances in understanding the unique clinical presentation, imaging findings, histopathology and clinical course of this relatively uncommon disease has led to international consensus regarding diagnosis and treatment. While corticosteroids remain the mainstay of treatment, several emerging novel therapies have been explored primarily in the context or relapsing and refractory cases. It is important that AIP be differentiated from other pancreatic conditions, especially since the clinical presentation may mimic pancreaticobiliary malignancies. Early recognition of this distinct entity and appropriate management can reduce the risk of complications and improve long-term outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.